The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan

European Journal of Surgical Oncology

Volumn 38, Issue 1, 2012, Pages 31-37

  Garami, Z ^a   Hascsi, Z ^b   Varga, J ^c   Dinya, T ^a   Tanyi, M ^a   Garai, I ^b   Damjanovich, L ^a   Galuska, L ^c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b SCANOMED LTD   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Change in disease stage; Early breast cancer; PET CT; Treatment planning

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CLASSIFICATION; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; TREATMENT PLANNING; TUMOR VOLUME; WHOLE BODY PET; WHOLE BODY TOMOGRAPHY;

ADULT; AGED; AXILLA; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; HUNGARY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 83955164256     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2011.09.002     Document Type: Article

References (30)

1. T. Beyer, D.W. Towsend, and T. Brun A combined PET/CT scanner for clinical oncology J Nucl Med 41 2000 1369 1379 (Pubitemid 30643379)
2. T.M. Blodgett, C.C. Meltzer, and D.W. Towsend PET/CT: form and function Radiology 242 2007 360 385 (Pubitemid 46150968)
3. H. Minn, and I. Soini (18-F) fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer Eur J Nuc Med 15 1989 61 66 (Pubitemid 19054851)
4. N. Avril, C.A. Rosé, and M. Schelling Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations J Clin Oncol 18 2000 3495 3502
5. H. Schirrmeister, T. Kühn, and A. Guhlmann Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures Eur J Nucl Med 28 2001 351 358
6. F.T. Cermik, A. Mavi, S. Basu, and A. Alavi Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer Eur J Nucl Med Mol Imaging 35 2008 475 483 (Pubitemid 351661670)
7. W.B. Eubank, and D.A. Mankoff Evolving role of positron emission tomography in breast cancer imaging Semin Nucl Med 35 2005 84 99 (Pubitemid 40568742)
8. A. Gil-Rendo, F. Martínez-Regueira, G. Zornoza, M.J. Garcia-Velloso, C. Beorlegui, and N. Rodriguez-Spiteri Association between [18F] fluorodeoxyglucose uptake and prognostic parameters in breast cancer Br J Surg 96 2009 166 170
9. P. Hendel, S. Cimarelli, A. Montella, C. Bouteille, and T. Mognetti Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors Int J Clin Oncol 15 2010 588 593
10. G. Zornoza, M.J. Garcia-Velloso, J. Sola, F.M. Regueira, L. Pina, and C. Beorlegni 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer EJSO 30 2004 15 19 (Pubitemid 38180986)
11. A.C. Voogd, F.J. van Oost, and E.J.T. Rutgers Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer Eur J Cancer 41 2005 2637 2644 (Pubitemid 41607554)
12. A.E. Guiliano, D.M. Kirgan, J.M. Guenther, and D.L. Morton Lymphatic mapping and sentinel lymphadenectomy for breast cancer Ann Surg 220 1994 391 398
13. J.J. Albertini, G.H. Lymann, and C. Cox Lymphatic mapping and sentinel node biopsy in the patient with breast cancer JAMA 276 1996 1818 1822 (Pubitemid 26406231)
14. S. Monzawa, S. Adachi, and K. Suzuki Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastasis: comparison with ultrasonography and contrast-enhanced CT Ann Nucl Med 23 2009 855 861
15. P.J. Lovrics, V. Chen, and G. Coates A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging patients with early stage breast cancer Ann Surg Oncol 11 2004 846 853
16. T.A. Heusner, S. Kuemmel, and S. Hahn Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients Eur J Nucl Med Mol Imaging 36 2009 1543 1550
17. R.L. Wahl, B.A. Siegel, R.E. Coleman, and C.G. Gatsonis Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET sutdy group J Clin Oncol 22 2004 277 285 (Pubitemid 41095092)
18. J. Kim, J. Lee, and E. Chang Selective sentinel node plus additional non-sentinel node biopsy based on an FDG-PET/CT scan in early breast cancer patients: single institutional experience World J Surg 33 2009 943 949
19. S. Ueda, H. Tsuda, and H. Asakawa Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer BMC Cancer 8 2008 165
20. S. Alvarez, E. Anorbe, P. Alcorta, F. López, I. Alonso, and J. Cortés Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review AJR 186 2006 1342 1348 (Pubitemid 46112571)
21. K.L. Cooper, S. Harnan, and Y. Meng Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis Eur J Surg Oncol 37 2011 187 198
22. K.L. Cooper, Y. Meng, and S. Harnan Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation Health Technol Assess 15 2011 1 134
23. Y. Meng, S. Ward, K. Cooper, S. Harnan, and L. Wyld Cost-effectiveness of MRI and PET imaging for the evaluation of axillary lymph node metastases in early stage breast cancer Eur J Surg Oncol 37 2011 40 46
24. A. Goldhirsch, J.N. Ingle, R.D. Gelber, A.S. Coates, B. Thürlimann, H.-J. Senn Panel members Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Onc 20 2009 1319 1329
25. B. Farris, S. Vidal-Sicart, and M. Velasco Incidence of internal mammary node metastases after a sentinel lymph node technique in breast cancer and its implication in the radiotherapy plan Int J Rad Oncol Biol Phys 60 2004 715 721 (Pubitemid 39311750)
26. M. Lonneux, I. Borbath, M. Berdiere, I.C. Kircove, and S. Pauwels The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer Clin Positron Imaging 3 2000 45 49
27. E.R. Port, H. Yeung, and M. Gonen 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma Ann Surg Oncol 13 2006 677 684
28. J. Dose, C. Bleckmann, and S. Bachmann Comparison of fluorodeoxyglucose positron emission tomography and conventional diagnostic procedures' for the detection of distant metastases in breast cancer patients Nucl Med Commun 23 2002 857 864
29. F. Puglisi, A. Follador, and A.M. Minisini Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications Ann Oncol 16 2005 263 266 (Pubitemid 40309307)
30. C.S. Yap, M.A. Seltzer, and C. Schiepers Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective J Nucl Med 42 2001 1334 1337 (Pubitemid 32852607)